

Sydney, Australia. 30 November, 2018.

## **PHEBRA LAUNCHES NEW BRAND OF PHOSPHATE TABLETS**

Phebra has announced the launch of its own brand of Phosphate 500mg effervescent tablets to replace the discontinued Phosphate Sandoz effervescent tablets.

Phebra has been working closely with the Innovation and Business Development team at Novartis to ensure a seamless transition from Phosphate Sandoz (originally supplied by Novartis) to the new Phebra brand of Phosphate effervescent tablets – ‘Phosphate Phebra’.

Phosphate Phebra is listed on the Pharmaceutical Benefits Scheme (PBS), for the treatment of Hypophosphataemic rickets, Vitamin D-resistant rickets, Familial hypophosphataemia and Hypercalcaemia.

“Phebra is pleased to be launching our Phosphate Phebra (monobasic sodium phosphate) effervescent tablets on to the Australian market,” Phebra’s Chief Executive Officer, Dr Mal Eutick, said today.

“We’ve been working in collaboration with the committed team at Novartis to ensure that Australian patients continue to have access to this clinically important medicine.”

### **About Phebra**

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

***At Phebra, we create critical medicines that save and improve lives.***

Phebra media contact: Richard Lenarduzzi +61 411 254 390